KORU Medical Systems (NASDAQ:KRMD) Upgraded to “Strong-Buy” at B. Riley

B. Riley upgraded shares of KORU Medical Systems (NASDAQ:KRMD) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Several other equities research analysts have also recently commented on KRMD. Piper Sandler restated a “neutral” rating and set a $4.50 price target on shares of KORU Medical Systems in a research note on Friday, February 14th. Craig Hallum increased their price objective on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Lake Street Capital increased their price objective on KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Finally, Canaccord Genuity Group increased their price objective on KORU Medical Systems from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, KORU Medical Systems has a consensus rating of “Buy” and a consensus price target of $4.70.

KORU Medical Systems Price Performance

KORU Medical Systems stock opened at $2.77 on Thursday. KORU Medical Systems has a 12 month low of $2.04 and a 12 month high of $5.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.99 and a quick ratio of 2.37. The business has a 50 day simple moving average of $3.94 and a 200-day simple moving average of $3.39. The stock has a market capitalization of $126.97 million, a PE ratio of -11.08 and a beta of 0.74.

Institutional Trading of KORU Medical Systems

Large investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in KORU Medical Systems in the third quarter valued at $34,000. JPMorgan Chase & Co. grew its holdings in KORU Medical Systems by 2,770.7% in the fourth quarter. JPMorgan Chase & Co. now owns 17,712 shares of the company’s stock valued at $68,000 after purchasing an additional 17,095 shares during the last quarter. Virtu Financial LLC acquired a new stake in KORU Medical Systems in the fourth quarter valued at $73,000. Vivaldi Capital Management LP acquired a new stake in KORU Medical Systems in the fourth quarter valued at $82,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of KORU Medical Systems during the fourth quarter valued at $84,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.